查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
全球女性避孕市場 - 2022-2029
市場調查報告書
商品編碼
1143409

全球女性避孕市場 - 2022-2029

Global Female Sterilization Procedures Market - 2022-2029
出版日期: | 出版商: DataM Intelligence | 英文 200 Pages | 商品交期: 約2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

市場概覽

英國的國民健康服務體系 (NHS) 指出，“女性絕育手術是為了永久防止懷孕而進行的手術”。輸卵管被阻塞或固定，以防止卵子到達精子並使其受精。

市場動態

對女性健康問題的認識不斷提高、人口增長以及研發力度的加大，正在加速全球女性絕育市場的增長。

女性避孕藥的研發和人口增長正在推動市場的增長。

女性避孕藥具的研發不斷增加正在推動全球市場的增長。例如，微針避孕皮膚貼片的開發，一種緩慢釋放激素的裝置，是一種簡單、長效的避孕方法，不需要醫療專業人員進行管理。貼在皮膚上1分鐘後，微針迅速從皮膚上的貼片上剝落，緩慢釋放左炔諾孕酮約1個月。同樣在抗體作為非激素避孕藥的研究中，北卡羅來納大學教堂山分校的研究人員開發了一種與精子結合的強效單克隆抗體，為女性提供了一種廉價的非激素避孕方法。我們的目標是提供另一種預防懷孕的非激素選擇。此外，不斷增長的世界人口增加了對永久避孕的需求。例如，根據美國人口普查，每 8 秒就有一個人出生，每 12 秒就有一個人死亡。土地、衛生服務和許多其他需求。

缺乏安全性和高成本正在減緩全球女性避孕藥具市場的增長。

但是，副作用、缺乏安全性以及女性絕育的高成本等幾個原因可能會減緩該市場在預測期內的增長。

COVID-19 影響分析

COVID-19 正在對全球市場增長產生負面影響，因為已經實施了限制措施來限制 COVID-19 的傳播，從而擾亂了全球供需鏈。此外，由於社會化法規的實施，預定的絕育程序被推遲或取消，對全球女性避孕藥具市場產生負面影響。

細分分析

預計在預測期間（2022-2029 年），外科手術將以最快的複合年增長率增長。

手術程序具有預測性，因為它們提供的優勢，例如是一種高效和永久的避孕方法，不影響性慾，不干擾性自發性。預計在此期間（2022 年）將主導全球市場-2029)。它也不會影響正常的荷爾蒙節律或生理機能。再者，微創手術安全，副作用少，風險小，療效高（99%），這將確保女性手術絕育在預測期內在全球市場的主導地位。我來了。

區域分析

北美地區主導著全球女性避孕藥具市場。

增加意外懷孕、主要市場參與者的存在以及北美更好的成本報銷政策有助於該地區在全球市場上的主導地位。例如，美國的意外懷孕率明顯高於許多其他發達國家。低收入女性、18-24 歲女性、同居女性和有色人種女性的意外懷孕率最高。在高收入女性、白人女性、受過大學教育的女性和已婚女性中，這一比例似乎最低。此外，根據疾控中心的數據，2020 年將有超過 3,613,647 人出生，出生率為 11.0/1000 人，出生率為 56.0/1000 名 15-44 歲女性，其中未婚母親將占到這一比例。超過 40.5%。

此外，我們使用 Medicaid 數據確定了 5,906 名接受宮腔鏡手術的女性和 23,965 名接受腹腔鏡手術的女性，平均年齡為 33 歲。此外，Hologic, Inc.、CONMED Corporation、Ethicon, Inc.、Cooper Surgical、Boston Scientific Corporation、Cardinal Health 和 American Medical Systems 等大公司在全球市場佔有很大份額。這些總部設在美國，確保了北美的主導地位。

競爭格局

主要參與者是： Bayer AG、Hologic, Inc.、CONMED Corporation、Ethicon, Inc.、Cooper Surgical、波士頓科學公司、Olympus Corporation、Pregna International、Cardinal Health 和 American Medical Systems。這些主要參與者通過創新、產品發布、合作、收購、合作等方式佔領了主要市場份額。例如，2021 年 11 月 30 日，Hologic 收購了 Bolder Surgical。同樣在 2022 年 8 月 18 日，拜耳的 Mirena 在美國獲得了延長避孕藥具使用的批准。

Hologic Inc.

概述。

Hologic 是領先的醫療技術公司之一，致力於研究和製造女性健康產品，包括用於診斷、手術和醫學成像的醫療設備。 Hologic 於 1985 年在美國馬薩諸塞州成立，是一家全球性公司，在超過 15 個國家設有辦事處，擁有 5,500 多名員工。

內容

第一章研究方法與範圍

  • 調查方法
  • 調查目的和範圍

第 2 章市場定義和概述

第 3 章執行摘要

第 4 章市場動態

  • 市場影響因素
    • 驅動程序
      • 提高認識
      • 人口增長
    • 約束因素
      • 缺乏安全性
      • 高成本
    • 商機
    • 影響分析

第五章行業分析

  • 波特五力分析
  • 供應鏈分析
  • 監管分析

第 6 章 COVID-19 分析

  • COVID-19 的市場分析
    • COVID-19 之前的市場情景
    • COVID-19 的當前市場情景
    • COVID-19 後或未來情景
  • COVID-19 期間的價格動態
  • 供需範圍
  • 大流行期間與市場相關的政府舉措
  • 製造商的戰略舉措
  • 總結

第 7 章按手術類型

  • 手術
  • 非手術手術
  • 其他

第 8 章最終用戶

  • 婦產中心
  • 門診中心
  • 其他

第 9 章按地區

  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 意大利
    • 西班牙
    • 其他歐洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 澳大利亞
    • 其他亞太地區
  • 中東和非洲

第 10 章競爭格局

  • 主要發展和戰略
  • 公司份額分析
  • 產品基準

第 11 章公司簡介

  • Hologic, Inc.
    • 公司簡介
    • 產品組合和描述
    • 主要亮點
    • 財務摘要
  • Bayer AG
  • CONMED Corporation
  • Ethicon, Inc.
  • Cooper Surgical
  • Boston Scientific Corporation
  • Olympus Corporation
  • Pregna International
  • Cardinal Health
  • American Medical Systems（*LIST NOT EXHAUSTIVE）

第12章 DataM

簡介目錄
Product Code: DMPH88

Market Overview

National Health Service (NHS) of the U.K states that female sterilization is an operation to prevent pregnancy permanently. The fallopian tubes are either clogged or latched to prevent the eggs from reaching the sperm and fertilizing.

Market Dynamics

The rising awareness about female health issues, the growing population, and the increasing research and development are accelerating the female sterilization procedures market growth globally.

The increasing research and development in female contraception procedures and the growing population propel the market growth.

The increasing research and development in female contraception procedures drive global market growth. For instance, the microneedle contraceptive skin patch development is a device that slow-releases hormones; that is a simple, long-acting form of contraception that does not need a health professional to be administered. Followed by pressing the patch to the skin for one minute, the microneedles will rapidly detach from the patch within the skin and slowly release levonorgestrel for about 1 month. Also, the research on antibodies as a non-hormonal contraceptive, the Scientists at the University of North Carolina at Chapel Hill are developing potent monoclonal antibodies that bind sperm to offer an inexpensive and non-hormonal form of female contraception, offering women another non-hormonal option to prevent pregnancies. Furthermore, the increasing population globally is increasing the need for permanent contraception. For instance, according to the US census, there is one birth every 8 seconds with one death every 12 seconds, and the current global population is ~8 billion, and at this rate will reach 9.8 billion by 2030, which will create a scarcity of food, land, medical services, and many other needs.

The lack of safety and the high cost slow the global female sterilization procedures market growth.

However, some reasons, like the side effects, lack safety, and the high cost of female sterilization procedures, are likely to slow down the growth of this market in the forecast period.

COVID-19 Impact Analysis

COVID-19 disturbed the global supply and demand chain, which has negatively impacted the global market growth as there were restrictions imposed to restrict the spread of COVID-19 infection. Furthermore, because of the socializing restrictions imposed, the planned sterilization procedures were either postponed or canceled, thereby negatively impacting the global female sterilization procedure market.

Segment Analysis

The surgical procedure is anticipated to grow at the fastest CAGR during the forecast period (2022-2029).

The surgical procedure is expected to dominate the global market throughout the forecast period (2022-2029), owing to the advantages offered by the surgical method, such as being a very effective and permanent method of contraception, does not affect sex drive, doesn't interfere with the spontaneity of sexual intercourse. There is no effect on your normal hormonal rhythms or periods. Furthermore, minimally invasive surgery makes it safe, with minimal side effects, risks, and high effectiveness (99%) method, ensuring the dominance of female surgical sterilization over the global market during the forecast period.

Geographical Analysis

The North American region commands the global female sterilization procedures market.

The factors include the growing number of unintended pregnancies, the presence of key market players, and better cost reimbursement policies in North America contribute to the dominance of this region over the global market. For instance, the unintended pregnancy rate is significantly higher in the United States than in many other developed countries. Unplanned pregnancy rates are highest among low-income women, women aged 18-24, cohabiting women, and women of color. Rates appear to be lowest among higher-income women, white women, college graduates, and married women. Furthermore, according to CDC, in 2020, over 3,613,647 births occurred, making the birth rate 11.0 per 1,000 population and the fertility rate 56.0 births per 1,000 women aged 15-44; out of these births, over 40.5% of mothers were unmarried.

Moreover, using the Medicaid data, researchers identified 5,906 women who had undergone hysteroscopic and 23,965 who had undergone laparoscopic sterilization, having an average age of 33. In addition, key market players such as Hologic, Inc., CONMED Corporation, Ethicon, Inc., Cooper Surgical, Boston Scientific Corporation, Cardinal Health, and American Medical Systems hold a large share of the global market. They are U.S.-based, ensuring North America`s dominance globally.

Competitive Landscape

Some key players are: Bayer AG, Hologic, Inc., CONMED Corporation, Ethicon, Inc., Cooper Surgical, Boston Scientific Corporation, Olympus Corporation, Pregna International, Cardinal Health, and American Medical Systems. These key players hold the major share of the market through innovations, product launches, collaborations, acquisitions, and alliances. For instance, in November 30, 2021, Hologic acquired Bolder Surgical. Also, in August 18, 2022, Mirena from Bayer secured approval in the US for an extended duration of use in contraception.

Hologic, Inc.

Overview:

Hologic, Inc. is among the leading medical technology companies involved in research and manufacturing products for women's health, including medical devices for diagnostics, surgery, and medical imaging. Hologic, Inc. is headquartered in Massachusetts, U.S. and was founded in 1985; it also has a global presence, With locations in over 15 countries and more than 5,500 employees globally.

Product Portfolio:

The product portfolio of Hologic, Inc. for female sterilization procedures has JustRight Surgical Stapler, Omni hysteroscope, CoolSeal Vessel Sealing Portfolio, Etc.

The global female sterilization procedures market report would provide access to approximately 40+ market data tables, 45+ figures, and in the range of 200 (approximate) pages.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increased Awareness
      • 4.1.1.2. Growing Population
    • 4.1.2. Restraints
      • 4.1.2.1. Lack of Safety
      • 4.1.2.2. High Cost
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturer's Strategic Initiatives
  • 6.6. Conclusion

7. By Procedure Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Procedure Type Segment
    • 7.1.2. Market Attractiveness Index, By Procedure Type Segment
  • 7.2. Surgical
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 7.3. Non-Surgical
  • 7.4. Others

8. By End User

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User Segment
    • 8.1.2. Market Attractiveness Index, By End User Segment
  • 8.2. Maternity Centers
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 8.3. Ambulatory Centers
  • 8.4. Others

9. By Region

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 9.1.2. Market Attractiveness Index, By Region
  • 9.2. North America
    • 9.2.1. Introduction
    • 9.2.2. Key Region-Specific Dynamics
    • 9.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Procedure Type
    • 9.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 9.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.2.5.1. The U.S.
      • 9.2.5.2. Canada
      • 9.2.5.3. Mexico
  • 9.3. Europe
    • 9.3.1. Introduction
    • 9.3.2. Key Region-Specific Dynamics
    • 9.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Procedure Type
    • 9.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 9.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.3.5.1. Germany
      • 9.3.5.2. The U.K.
      • 9.3.5.3. France
      • 9.3.5.4. Italy
      • 9.3.5.5. Spain
      • 9.3.5.6. Rest of Europe
  • 9.4. South America
    • 9.4.1. Introduction
    • 9.4.2. Key Region-Specific Dynamics
    • 9.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Procedure Type
    • 9.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 9.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.4.5.1. Brazil
      • 9.4.5.2. Argentina
      • 9.4.5.3. Rest of South America
  • 9.5. Asia Pacific
    • 9.5.1. Introduction
    • 9.5.2. Key Region-Specific Dynamics
    • 9.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Procedure Type
    • 9.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 9.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.5.5.1. China
      • 9.5.5.2. India
      • 9.5.5.3. Japan
      • 9.5.5.4. Australia
      • 9.5.5.5. Rest of Asia Pacific
  • 9.6. Middle East and Africa
    • 9.6.1. Introduction
    • 9.6.2. Key Region-Specific Dynamics
    • 9.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Procedure Type
    • 9.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User

10. Competitive Landscape

  • 10.1. Key Developments and Strategies
  • 10.2. Company Share Analysis
  • 10.3. Product Benchmarking

11. Company Profiles

  • 11.1. Hologic, Inc.
    • 11.1.1. Company Overview
    • 11.1.2. Product Portfolio and Description
    • 11.1.3. Key Highlights
    • 11.1.4. Financial Overview
  • 11.2. Bayer AG
  • 11.3. CONMED Corporation
  • 11.4. Ethicon, Inc.
  • 11.5. Cooper Surgical
  • 11.6. Boston Scientific Corporation
  • 11.7. Olympus Corporation
  • 11.8. Pregna International
  • 11.9. Cardinal Health
  • 11.10. American Medical Systems(*LIST NOT EXHAUSTIVE)

12. DataM Intelligence

  • 12.1. Appendix
  • 12.2. About Us and Services
  • 12.3. Contact Us